menu
    • menu
    [{"orgOrder":0,"company":"Gate Neurosciences","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zelquistinel","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gate Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gate Neurosciences \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Gate Neurosciences \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Gate Neurosciences","sponsor":"Beacon Biosignals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Zelquistinel","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gate Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gate Neurosciences \/ Beacon Biosignals","highestDevelopmentStatusID":"8","companyTruncated":"Gate Neurosciences \/ Beacon Biosignals"},{"orgOrder":0,"company":"Syndeio Biosciences","sponsor":"Catalio Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Zelquistinel","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Syndeio Biosciences","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.089999999999999997,"dosageForm":"Oral Tablet","sponsorNew":"Syndeio Biosciences \/ Catalio Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Syndeio Biosciences \/ Catalio Capital Management"},{"orgOrder":0,"company":"Ronald M Burch MD PhD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zelquistinel","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Ronald M Burch MD PhD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ronald M Burch MD PhD \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ronald M Burch MD PhD \/ Inapplicable"},{"orgOrder":0,"company":"Syndeio Biosciences","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Zelquistinel","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Syndeio Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syndeio Biosciences \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Syndeio Biosciences \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Syndeio Biosciences","sponsor":"Dr. Vince Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Zelquistinel","moa":"NMDA receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syndeio Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syndeio Biosciences \/ Dr. Vince Clinical Research","highestDevelopmentStatusID":"6","companyTruncated":"Syndeio Biosciences \/ Dr. Vince Clinical Research"}]

    Find Clinical Drug Pipeline Developments & Deals for Zelquistinel

    Menu

    Zelquistinel

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Syndeio Biosciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Syndeio Biosciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zelquistinel

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Worldwide Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of GATE-251 vs Placebo in MDD with Comorbid Anxiety & Insomnia

                            Details : Zelquistinel is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Depressive Disorder, Major.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 11, 2025

                            Lead Product(s) : Zelquistinel

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Worldwide Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Syndeio Biosciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Syndeio Biosciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zelquistinel

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Dr. Vince Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics of GATE-251 in Fasted or Fed State

                            Details : Zelquistinel is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 01, 2025

                            Lead Product(s) : Zelquistinel

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Dr. Vince Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Syndeio Biosciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Syndeio Biosciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zelquistinel

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Catalio Capital Management

                            Deal Size : $90.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Syndeio Biosciences Launches to Pioneer Synapse-Targeted Neurotherapeutics

                            Details : The net procceds will be used for Syndeio’s lead candidate, GATE-251 aka zelquistinel, an orally bioavailable positive allosteric modulator of the NMDA receptor, to treat major depressive disorder.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 27, 2025

                            Lead Product(s) : Zelquistinel

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Catalio Capital Management

                            Deal Size : $90.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Gate Neurosciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Gate Neurosciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zelquistinel

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Worldwide Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 09, 2024

                            Lead Product(s) : Zelquistinel

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Worldwide Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Gate Neurosciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Gate Neurosciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zelquistinel

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Beacon Biosignals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Gate Neurosciences Partners with Beacon Biosignals on EEG Biomarkers for Depression

                            Details : Beacon's Dreem™ 3S headband will be used to analyze EEG and sleep in depressed patients during Phase 2 trials of zelquistinel, an NMDA receptor modulator.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 24, 2024

                            Lead Product(s) : Zelquistinel

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Beacon Biosignals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ronald M Burch MD PhD

                            Country arrow
                            ESCRS
                            Not Confirmed

                            Ronald M Burch MD PhD

                            Country arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zelquistinel

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Tolerability of GATE-251 in Normal Human Volunteers

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 29, 2021

                            Lead Product(s) : Zelquistinel

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Gate Neurosciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Gate Neurosciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zelquistinel

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AGN-241751 in the Treatment of Major Depressive Disorder

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 31, 2018

                            Lead Product(s) : Zelquistinel

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Gate Neurosciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Gate Neurosciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zelquistinel

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AGN-241751 in the Treatment of Major Depressive Disorder

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 13, 2018

                            Lead Product(s) : Zelquistinel

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth